A commercial-stage biopharmaceutical company dedicated to the identification, development & commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the CNS.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Overvalued. If you want in on the future of CNS research and production invest in a broader, safer buy like STEM. They will benefit from the production and storage regardless of who comes up with the new tech. Short the fall. Not sure when or if I would buy back in.
I don't see STEM being a safer bet. STEM is taking one approach (stem cells), while Acorda is also looking at other approaches to accomplish the same thing. Just last week they announced success in a trial to block scar tissue from forming in spinal injuries.